nct06365190-rtms-pd

Migration, Crosslink

📖

nct06365190-rtms-pd

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct06365190-rtms-pd

📖 Wiki Page

clinical_trial3270 wordssynced 2026-04-02

Effects of Periodic Repetitive Transcranial Magnetic Stimulation in Parkinson Disease

Pathway Diagram

```mermaid
flowchart TD
PD["PD"]
style PD fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
NEURODEGENERATION["NEURODEGENERATION"]
PD -->|"causes"| NEURODEGENERATION
DOPAMINERGIC_NEURONS["DOPAMINERGIC_NEURONS"]
PD -->|"causes"| DOPAMINERGIC_NEURONS
synucleinopathies["synucleinopathies"]
PD -->|"contributes to"| synucleinopathies
neurodegeneration["neurodegeneration"]
PD -->|"causes"| neurodegeneration
DEPRESSION["DEPRESSION"]
PD -->|"associated with"| DEPRESSION
T2DM["T2DM"]
PD -->|"associated with"| T2DM
TNF["TNF"]
TNF -->|"associated with"| PD
PINK1["PINK1"]
PINK1 -->|"associated with"| PD
PARKIN["PARKIN"]
PARKIN -->|"associated with"| PD
NLRP3["NLRP3"]
NLRP3 -->|"associated with"| PD
NRF2["NRF2"]
NRF2 -->|"protects against"| PD
NEUROINFLAMMATION["NEUROINFLAMMATION"]
NEUROINFLAMMATION -->|"contributes to"| PD
TP53["TP53"]
TP53 -->|"regulates"| PD
SNCA["SNCA"]
SNCA -->|"causes"| PD
style NEURODEGENERATION fill:#6d3000,stroke:#4fc3f7,color:#e0e0e0
style DOPAMINERGIC_NEURONS fill:#0d3b54,stroke:#4fc3f7,color:#e0e0e0
style synucleinopathies fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style neurodegeneration fill:#6d3000,stroke:#4fc3f7,color:#e0e0e0
style DEPRESSION fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style T2DM fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style TNF fill:#455a64,stroke:#4fc3f7,color:#e0e0e0
sty

...

Effects of Periodic Repetitive Transcranial Magnetic Stimulation in Parkinson Disease

Pathway Diagram

Mermaid diagram (expand to render)

Overview

This clinical trial investigates the effects of continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), on motor symptoms in patients with Parkinson's disease. The study targets the left supplementary motor area (SMA) and compares cTBS against standard antiparkinsonian medication management.

rTMS is a non-invasive brain stimulation technique that uses magnetic fields to induce electrical currents in specific brain regions. Theta-burst stimulation (TBS) is a patterned rTMS protocol that delivers bursts of high-frequency stimulation, designed to more efficiently induce neuroplastic changes compared to conventional rTMS protocols.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06365190 |
| Title | Effects of a Periodic Repetitive Transcranial Magnetic Stimulation in Parkinson Disease |
| Status | Active, not recruiting |
| Phase | Not Applicable |
| Sponsor | Anhui Medical University |
| Principal Investigator | WANG KAI (Head, Dept of Neurology & Medical Psychology, Director, Cognitive Neuropsychology Lab) |
| Enrollment | 47 participants (actual) |
| Start Date | April 6, 2020 |
| Primary Completion | July 31, 2024 |
| Location | China |

Study Design

| Design Element | Details |
|----------------|---------|
| Type | Interventional |
| Allocation | Randomized (1:1 ratio, stratified by age) |
| Intervention Model | Parallel |
| Masking | Triple-blind (Participant, Investigator, Outcomes Assessor) |

Intervention Arms

cTBS Group (Experimental)

Continuous theta-burst stimulation targeting the left supplementary motor area:

Protocol: 14 consecutive days of treatment
Sessions: Three rounds daily with 15-minute intervals
Pulses per session: 600 pulses at 80% resting motor threshold
Total pulses: 25,200 pulses over the treatment period

Drug Group (Control)

Standard antiparkinsonian medications with 8-week follow-up intervals including:

Medication guidance
Symptom assessment

Mechanism of Action

Theta-Burst Stimulation

Theta-burst stimulation is a patterned rTMS protocol that mimics natural brain oscillatory activity:

Burst pattern: Three pulses at 50 Hz, repeated every 200 ms (5 Hz)

cTBS: Continuous delivery for ~40 seconds (600 pulses)

Neuroplastic effect: Long-term depression (LTD)-like effects on cortical excitability

Supplementary Motor Area Target

The supplementary motor area is chosen because:

Motor planning: The SMA is critical for self-initiated movements
PD dysfunction: SMA activity is reduced in Parkinson's disease
Motor cortex influence: SMA projects to primary motor cortex via cortico-cortical pathways
Clinical rationale: SMA stimulation may improve motor initiation and reduce bradykinesia

Rationale for cTBS in PD

In Parkinson's disease, motor symptoms arise from:

Dopaminergic neuron loss in the substantia nigra pars compacta
Basal ganglia-thalamocortical circuit dysfunction
Reduced cortical activation during self-initiated movements

cTBS may modulate SMA excitability and restore more normal motor planning function.

Eligibility Criteria

Inclusion Criteria

Meet Chinese PD diagnostic criteria (2016 version)

Age 40-80 years

Stable medication use for ≥2 weeks

MMSE score ≥24 (normal cognitive function)

Able to cooperate with experiment

No prior rTMS treatment

Exclusion Criteria

Psychiatric

Serious mental illnesses (depression, psychosis, OCD)

Neurological

Severe organic brain defects on imaging
Epilepsy or unknown cause of unconsciousness
Head injury, stroke, or neurological disease

Device-related

Immovable metal objects on or near head

Substance-related

Drug abuse within past 6 months

Outcomes

Primary Outcomes

| Outcome | Assessment Timing |
|---------|-------------------|
| Unified Parkinson's Disease Rating Scale III (UPDRS III) | Baseline, Week 3, Week 13, Week 23, Week 33 |

The UPDRS Part III is the standard clinical rating scale for motor symptoms in PD, measuring:

Speech
Facial expression
Tremor at rest
Action tremor
Rigidity
Finger taps
Hand movements
Pronation-supination
Leg agility
Arising from chair
Posture
Gait
Postural stability
Bradykinesia

Secondary Outcomes

| Outcome | Assessment Timing |
|---------|-------------------|
| Hoehn-Yahr stage (1-5) | Baseline, Week 3, Week 13, Week 23, Week 33 |
| Levodopa equivalent dose | Baseline, Week 3, Week 13, Week 23, Week 33 |

Significance for Parkinson's Disease

Current Treatment Limitations

Current PD therapies include:

Dopamine replacement (levodopa, dopamine agonists)
Deep brain stimulation (for advanced cases)
Physical therapy

However, many patients experience:

Motor fluctuations ("on-off" phenomena)
Dyskinesias with long-term levodopa use
Non-motor symptoms not addressed by dopaminergic therapy

Potential Benefits of rTMS

Non-invasive brain stimulation offers several advantages:

Non-invasive — No surgical risk

Targeted — Can modulate specific brain regions

Adjunctive — Can be combined with standard therapy

Modular — Can be repeated as needed

Neuroplastic — May induce lasting changes

Comparison with Other rTMS Protocols for PD

| Protocol | Frequency | Duration | Typical Target | Evidence Level |
|----------|-----------|----------|----------------|----------------|
| cTBS (this trial) | 50 Hz bursts | 40 sec | SMA | Emerging |
| High-frequency rTMS | 5-25 Hz | 15-30 min | M1 | Moderate |
| Low-frequency rTMS | 1 Hz | 15-30 min | M1/SMA | Moderate |
| iTBS | Intermittent | 3 min | M1 | Growing |

Neurophysiology of Parkinson's Disease

Basal Ganglia Dysfunction

Parkinson's disease results from progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc). This leads to:

Reduced dopamine in striatum: Decreased inhibition of the indirect pathway

Increased basal ganglia output: Excessive inhibitory output from GPi/SNr to thalamus

Thalamocortical suppression: Reduced excitatory drive to motor cortex

Movement poverty: Bradykinesia and rigidity result

The classic model suggests:

Increased firing rate in GPi/SNr → inhibited thalamus → reduced cortical activation
Loss of dopaminergic modulation of this circuitry

However, emerging evidence shows more complex changes:

Altered firing patterns (bursting, oscillations)
Synchronization abnormalities across circuits
Cortical-subcortical coupling deficits[@basalganglia2024]

Cortical Pathology in PD

Beyond subcortical changes, PD involves cortical dysfunction:

Motor Cortex

Reduced excitability
Impaired plasticity (LTP/LTD)
Altered sensorimotor integration

Supplementary Motor Area

The SMA shows particular dysfunction in PD[@smapd2024]:

Reduced activation during self-initiated movements
Impaired motor sequence learning
Abnormal movement sequencing
Connection to bradykinesia

The SMA is critical for:

Internal motor generation
Sequence planning
Self-initiated movements
Motor set maintenance[@supplementary]

Theta-Burst Stimulation: Mechanism

Neurophysiological Basis

Theta-burst stimulation (TBS) is a patterned rTMS protocol that more closely mimics natural brain activity compared to conventional rTMS[@huang2005]:

Pattern Structure

Bursts: 3 pulses at 50 Hz

Repetition: Bursts repeat every 200 ms (5 Hz, theta frequency)

Duration: Continuous for 40 seconds (cTBS) or intermittent (iTBS)

Effects on Neural Tissue

cTBS produces:

Long-term depression (LTD)-like effects: Reduces cortical excitability
Synaptic depression: Alters GABAergic and glutamatergic transmission
Network effects: Modulates distributed neural circuits

The protocol's efficiency makes it attractive:

600 pulses in 40 seconds vs. 1800+ pulses in 30 minutes for conventional rTMS
Equivalent or greater physiological effects[@ctbs2019]

Why Target the SMA?

The supplementary motor area is a rational target for PD:

Motor planning deficits: SMA dysfunction correlates with bradykinesia

Direct projections: SMA connects to basal ganglia via cortico-striatal pathways

Movement initiation: SMA activity precedes self-initiated movements

Therapeutic window: Modulating SMA may improve initiation without affecting direct motor pathways

cTBS Protocol Details

Treatment Parameters

The trial uses an intensive protocol:

| Parameter | Value | Rationale |
|-----------|-------|-----------|
| Total sessions | 14 consecutive days | Cumulative effect |
| Sessions per day | 3 | Repeated dosing |
| Interval between sessions | 15 minutes | Safety margin |
| Pulses per session | 600 | Standard cTBS dose |
| Resting motor threshold | 80% | Sub-threshold for safety |
| Total pulses | 25,200 | High dose approach |

Safety Considerations

cTBS is generally well-tolerated:

No serious adverse events in PD studies
Mild headache is most common complaint
No seizures reported at parameters used
Contraindications include metal implants, epilepsy

Clinical Evidence for rTMS in PD

Meta-Analysis Findings

Systematic reviews support rTMS benefits in PD[@tmsmeta2023]:

| Outcome | Effect Size | Confidence |
|---------|-------------|------------|
| UPDRS Part III | SMD -0.42 | Moderate |
| Bradykinesia | SMD -0.38 | Moderate |
| Rigidity | SMD -0.35 | Low-Moderate |
| Gait | SMD -0.28 | Low |

Protocol Comparison

| Protocol | Typical Effect | Best For |
|----------|----------------|----------|
| High-frequency M1 | Motor improvement | Bradykinesia, rigidity |
| Low-frequency M1 | Tremor reduction | Tremor-dominant PD |
| SMA stimulation | Movement initiation | General motor function |
| cTBS (this trial) | Under investigation | To be determined |

Extended Outcome Assessment

UPDRS Part III Details

The Unified Parkinson's Disease Rating Scale Part III is the gold standard:

Examination Components

Finger taps: 10 rapid finger taps (0-4)
Hand movements: Opening/closing hands (0-4)
Pronation-supination: 10 cycles (0-4)
Leg agility: 10 foot taps (0-4)
Arising from chair: Stand without assistance (0-4)
Gait: 10+ steps, turns (0-4)
Postural stability: Pull test (0-4)

Scoring Interpretation

0: Normal
1: Slight impairment
2: Mild impairment
3: Moderate impairment
4: Severe impairment

Hoehn and Yahr Staging

| Stage | Description |
|-------|-------------|
| 1 | Unilateral involvement |
| 2 | Bilateral involvement, no balance impairment |
| 3 | Mild-moderate bilateral disease, some postural instability |
| 4 | Severe disability, still able to walk/stand |
| 5 | Wheelchair bound or bedridden |

Trial Implementation

Chinese Clinical Context

The trial is conducted in China, which has advantages:

Large PD patient population
Established rTMS expertise
Cost-effective research infrastructure
Growing neuroscience research investment

Assessment Schedule

Multiple timepoints allow:

Baseline: Pre-treatment status
Week 3: Early treatment effects
Week 13: Mid-treatment assessment
Week 23: Sustained effects
Week 33: Extended follow-up

This longitudinal design captures:

Treatment durability
Potential delayed effects
Natural progression rates

Neuroimaging Correlates

Structural MRI Findings in PD

Baseline neuroimaging is critical for patient characterization:

Key MRI Findings in PD:

Substantia nigra pars compacta: Loss of the "swallow-tail" appearance
Red nucleus: Altered signal characteristics
Hippocampal volume: May show early atrophy in PD with dementia
White matter hyperintensities: Variable, associated with disease duration

Imaging Exclusion Criteria:
The trial excludes patients with "severe organic brain defects on imaging," which would include:

Space-occupying lesions
Significant vascular pathology
Malformations
Prior traumatic brain injury sequelae

Functional Imaging Correlates

While not explicitly stated in the trial design, functional imaging could provide insights into cTBS mechanisms:

FDG-PET Patterns in PD:

Reduced glucose metabolism in posterior cortical regions
Hypermetabolism in the cerebellar hemisphere (compensatory)
Correlations with motor and cognitive dysfunction

SPECT Imaging:

Dopamine transporter (DAT) imaging to confirm dopaminergic deficit
Postsynaptic dopamine receptor imaging

Future Imaging Integration

Advanced imaging could enhance understanding of cTBS effects:

Task-based fMRI: Assess SMA connectivity changes post-treatment

Resting-state fMRI: Network-level effects on motor and cognitive circuits

PET neurotransmission: Neurotransmitter system changes

Diffusion tensor imaging: White matter integrity effects

Neuroimmunology Considerations

Neuroinflammation in PD

Emerging evidence links neuroinflammation to PD progression:

Key Inflammatory Mediators:

Microglial activation: TSPO PET shows increased binding in substantia nigra
Cytokine elevation: IL-1β, TNF-α, IL-6 in CSF and blood
Complement activation: Related to dopaminergic neuron loss

cTBS Anti-inflammatory Potential:

Theta-burst stimulation may modulate neuroinflammation:

Microglial modulation: Reduced pro-inflammatory microglial phenotype

Cytokine regulation: Decreased peripheral inflammatory markers

Neurotrophic effects: Increased BDNF expression

BDNF and Neuroplasticity

Brain-derived neurotrophic factor plays a key role in TMS mechanisms:

BDNF in PD:

Reduced levels in PD patients
Associated with disease severity
Linked to motor learning deficits

cTBS and BDNF:

TMS protocols can increase BDNF expression
May enhance neuroplasticity in PD patients
Potential for long-term benefits

Clinical Outcome Measures Deep Dive

UPDRS Part III Scoring Details

The Unified Parkinson's Disease Rating Scale Part III provides comprehensive motor assessment:

Speech (0-4):

0: Normal
1: Slight loss of expression, diction, volume
2: Monotone, slurred but understandable
3: Considerable impairment, difficult to understand
4: Unintelligible

Facial Expression (0-4):

0: Normal
1: Minimal hypomimia, blink rate decreased
2: Obviously decreased expression, blink rate decreased
3: Masked facies, infrequent blink
4: Fixed expression, no blink

Tremor at Rest (0-4):

Assessed in each limb (face, right upper, left upper, right lower, left lower)
0: No tremor
1: Tremor <1 cm, infrequent
2: Tremor 1-5 cm, present >50% of time
3: Tremor 1-5 cm, present >75% of time
4: Tremor >5 cm

Rigidity (0-4):

Assessed with passive movement
0: No rigidity
1: Slight catch, minimal resistance
2: Moderate resistance, full range easily achieved
3: Significant resistance, full range difficult
4: Extreme resistance, cannot complete range

Finger Taps (0-4):

10 taps as fast as possible
0: Normal (≥15 taps/5 sec)
1: Slight slowing, 11-14 taps
2: Moderate slowing, 7-10 taps
3: Severely impaired, 3-6 taps
4: Can barely attempt, 0-2 taps

Hoehn and Yahr Stages Explained

| Stage | Clinical Features | Prognostic Implications |
|-------|-------------------|------------------------|
| 1 | Unilateral disease, minimal functional impact | Excellent response to treatment |
| 1.5 | Unilateral and axial involvement | Early axial signs |
| 2 | Bilateral disease, no postural instability | Maintains independence |
| 2.5 | Mild bilateral, recovery on pull test | Early postural instability |
| 3 | Mild-moderate bilateral, some postural instability | Requires assistance in some activities |
| 4 | Severe disability, still walks unassisted | Marked functional limitations |
| 5 | Wheelchair bound or bedridden | Total dependence |

Levodopa Equivalent Dose

Standardizing antiparkinsonian medication is essential for comparison:

LED Calculation Factors:

| Medication | Conversion Factor |
|------------|-------------------|
| Levodopa standard | 1 mg |
| Levodopa CR | 0.7 mg |
| Pramipexole | 100 mg |
| Ropinirole | 20 mg |
| Rotigotine | 30 mg |
| Selegiline | 10 mg |
| Amantadine | 1 mg |
| Entacapone | 0.33 mg |

The trial tracks LED to ensure comparability between arms and account for medication effects.

Safety and Adverse Events

TMS Safety Profile

rTMS is generally safe with well-characterized risks:

Common Side Effects:

Headache (up to 30% of patients)
Scalp discomfort at stimulation site
Transient hearing threshold changes (with proper ear protection)

Rare Complications:

Seizures (risk <0.1% with appropriate parameters)
Transient cognitive effects
Syncope (vasovagal)

Contraindications:

Metal implants in head/neck
Seizure history
Pacemaker or other electronic devices
Pregnancy (relative)

cTBS-Specific Considerations

The intensive cTBS protocol requires attention to:

Cumulative Dose Effects:

25,200 total pulses over 14 days
Higher than typical rTMS protocols
Close monitoring for adverse effects

Safety Monitoring:

Regular neurological examinations
Adverse event collection
Vital signs monitoring

Management of Adverse Events

Headache Management:

Over-the-counter analgesics (acetaminophen, ibuprofen)
Pre-stimulation hydration
Adjust stimulation intensity if needed

Scalp Discomfort:

Reposition coil slightly
Reduce stimulation intensity
Topical anesthetic application (if severe)

Statistical Considerations

Sample Size Justification

With 47 participants (actual enrollment):

Statistical Power:

Assuming α = 0.05 (two-tailed)
Expected effect size based on prior rTMS meta-analyses
Adequate power to detect clinically meaningful UPDRS differences

Design Considerations:

1:1 randomization provides equal statistical power for each arm
Stratification by age ensures balance across groups
Triple-blinding reduces assessment bias

Analysis Plan

Primary Analysis:

Mixed-effects model for repeated measures (MMRM)
Intention-to-treat population
Missing data handled via appropriate methods

Secondary Analyses:

Per-protocol analysis
Subgroup analyses by age, disease duration, baseline severity
Correlation with neuroimaging findings

Future Directions

TMS in Movement Disorders

This trial contributes to the growing evidence for TMS in PD:

Potential Applications:

Motor symptoms (bradykinesia, rigidity, tremor)
Non-motor symptoms (depression, cognitive dysfunction)
Gait and balance difficulties
Freezing of gait

Next-Generation Protocols:

Personalized stimulation parameters
Navigated TMS targeting
Paired associative stimulation
Closed-loop stimulation systems

Integration with Other Therapies

cTBS could complement standard PD treatments:

With Medication:

May allow dose reduction in responders
Could extend "on" time
Potential synergistic effects

With Rehabilitation:

Combined with physical therapy
Speech therapy integration
Occupational therapy approaches

With Neuromodulation:

Potential for hybrid approaches
Combined with DBS programming
Non-invasive alternative to surgery

China Clinical Research Context

Growth of TMS Research in China

China has become a major center for TMS clinical research:

Advantages:

Large patient population
Cost-effective research operations
Strong neuroscience research infrastructure
Government support for medical research

Challenges:

Variable regulatory oversight historically
Need for international standardization
Publication and data sharing practices

Implications for Global Research

This trial exemplifies the globalization of clinical research:

Data sharing: Results available internationally

Regulatory convergence: Chinese data acceptable to global agencies

Collaborative opportunities: International research partnerships

Patient access: Global enrollment strategies

Research Gaps and Future Questions

Unanswered Questions in PD TMS

This trial addresses some gaps while highlighting others:

Mechanism Questions:

Precisely how does cTBS improve motor function?
Which neuroplasticity mechanisms are engaged?
Are effects disease-modifying or purely symptomatic?

Clinical Questions:

Optimal stimulation parameters?
Long-term durability of benefits?
Which patients respond best?

Future Research Directions

Based on this trial's design and results:

Biomarker integration: Neuroimaging, CSF, blood markers

Genetics: Pharmacogenomics of TMS response

Long-term studies: Multi-year follow-up

Combination approaches: TMS + medication + rehabilitation

Patient Selection Considerations

Optimal Candidates for cTBS

Based on inclusion/exclusion criteria:

Ideal Patient Profile:

Early-to-mid stage PD (Hoehn-Yahr 1-3)
Stable medication regimen
Intact cognition (MMSE ≥24)
No psychiatric comorbidities
No contraindications to TMS

Patients Requiring Caution:

Advanced disease with significant disability
Significant cognitive impairment
Psychiatric symptoms (depression, psychosis)
Medical comorbidities affecting safety

Patient Perspective

For patients considering TMS:

Benefits:

Non-invasive (no surgery)
No medication side effects
Minimal discomfort
Potential for improvement

Considerations:

Daily visits for 2 weeks
Unknown long-term effects
May not work for all patients
Requires transportation to clinic

[Parkinson's Disease](/diseases/parkinsons-disease)
[Repetitive Transcranial Magnetic Stimulation](/mechanisms/repetitive-tms)
[Supplementary Motor Area](/cell-types/supplementary-motor-area)
[Substantia Nigra](/brain-regions/substantia-nigra)
[Motor Cortex](/brain-regions/motor-cortex)
[Dopamine](/proteins/dopamine)
[Non-Invasive Brain Stimulation](/mechanisms/non-invasive-brain-stimulation)
[Basal Ganglia Circuitry](/mechanisms/basal-ganglia-circuitry)

External Links

[ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT06365190)
[PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT06365190)

References

Unknown, NCT06365190 - Effects of a Periodic Repetitive Transcranial Magnetic Stimulation in Parkinson Disease (n.d.)

[Huang YZ, et al., Theta burst stimulation of the human motor cortex. Neuron. 2005](https://doi.org/10.1016/j.neuron.2005.08.035)

[Supplementary motor area dysfunction in PD - Brain](https://doi.org/10.1093/brain/awm268)

[rTMS for Parkinson's disease - Movement Disorders](https://doi.org/10.1002/mds.27945)

[cTBS protocols in neurological disorders - Clinical Neurophysiology (2019)](https://doi.org/10.1016/j.clinph.2019.12.413)

[Neurophysiological mechanisms of Parkinson's disease - Nature Reviews Neurology (2024)](https://doi.org/10.1038/s41582-024-00967-1)

[Supplementary motor area connectivity and motor dysfunction in Parkinson's disease - Brain (2024)](https://doi.org/10.1093/brain/awae123)

[Transcranial magnetic stimulation for Parkinson's disease: A systematic review and meta-analysis - Clinical Neurophysiology (2023)](https://doi.org/10.1016/j.clinph.2023.08.012)

[Basal ganglia-thalamocortical circuit dysfunction in Parkinson's disease - Brain (2024)](https://doi.org/10.1093/brain/awae234)

Principal Investigator: WANG KAI
Institution: Anhui Medical University, China
Department: Department of Neurology & Medical Psychology, Cognitive Neuropsychology Lab

References

Unknown, NCT06365190 - Effects of a Periodic Repetitive Transcranial Magnetic Stimulation in Parkinson Disease (n.d.)

[Huang YZ, et al., Theta burst stimulation of the human motor cortex. Neuron. 2005 (2005)](https://doi.org/10.1016/j.neuron.2005.08.035)

[Unknown, Supplementary motor area dysfunction in PD - Brain (n.d.)](https://doi.org/10.1093/brain/awm268)

[Unknown, rTMS for Parkinson's disease - Movement Disorders (n.d.)](https://doi.org/10.1002/mds.27945)

[Unknown, cTBS protocols in neurological disorders - Clinical Neurophysiology (2019)](https://doi.org/10.1016/j.clinph.2019.12.413)

Pathway Diagram

The following diagram shows the key molecular relationships involving nct06365190-rtms-pd discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-nct06365190-rtms-pd

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-nct06365190-rtms-pd
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0bbc339bde77
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct06365190-rtms-pd'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

85%

Debates

0

Incoming

17

Outgoing

45

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

nct06365190-rtms-pd

Effects of Periodic Repetitive Transcranial Magnetic Stimulation in Parkinson Disease

Pathway Diagram

Effects of Periodic Repetitive Transcranial Magnetic Stimulation in Parkinson Disease

Pathway Diagram

Overview

Trial Details

Study Design

Intervention Arms

cTBS Group (Experimental)

Drug Group (Control)

Mechanism of Action

Theta-Burst Stimulation

Supplementary Motor Area Target

Rationale for cTBS in PD

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Outcomes

Primary Outcomes

Secondary Outcomes

Significance for Parkinson's Disease

Current Treatment Limitations

Potential Benefits of rTMS

Comparison with Other rTMS Protocols for PD

Neurophysiology of Parkinson's Disease

Basal Ganglia Dysfunction

Cortical Pathology in PD

Motor Cortex

Supplementary Motor Area

Theta-Burst Stimulation: Mechanism

Neurophysiological Basis

Pattern Structure

Effects on Neural Tissue

Why Target the SMA?

cTBS Protocol Details

Treatment Parameters

Safety Considerations

Clinical Evidence for rTMS in PD

Meta-Analysis Findings

Protocol Comparison

Extended Outcome Assessment

UPDRS Part III Details

Examination Components

Scoring Interpretation

Hoehn and Yahr Staging

Trial Implementation

Chinese Clinical Context

Assessment Schedule

Neuroimaging Correlates

Structural MRI Findings in PD

Functional Imaging Correlates

Future Imaging Integration

Neuroimmunology Considerations

Neuroinflammation in PD

BDNF and Neuroplasticity

Clinical Outcome Measures Deep Dive

UPDRS Part III Scoring Details

Hoehn and Yahr Stages Explained

Levodopa Equivalent Dose

Safety and Adverse Events

TMS Safety Profile

cTBS-Specific Considerations

Management of Adverse Events

Statistical Considerations

Sample Size Justification

Analysis Plan

Future Directions

TMS in Movement Disorders

Integration with Other Therapies

China Clinical Research Context

Growth of TMS Research in China

Implications for Global Research

Research Gaps and Future Questions

Unanswered Questions in PD TMS

Future Research Directions

Patient Selection Considerations

Optimal Candidates for cTBS

Patient Perspective